Treatment of infections caused by antimicrobial-resistant gram-positive bacteria

American Journal of the Medical Sciences

Volumn 340, Issue 3, 2010, Pages 209-217

  Kinney, Karen K ^a  

^a Infectious Diseases Section (111 C)   (United States)

Author keywords

HVISA; MRSA; Resistance; Treatment; VRE

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 77956826839     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181e99aa4     Document Type: Conference Paper

References (109)

1. Draghi DC, Sheehan DJ, Hogan P, et al. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: Results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2005;49:5024-5032
2. Jones RN, Ross JE, Castanheira M, et al. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2008;62:416-426
3. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39: 309-317
4. Klevens RM, Edwards JR, Tenover FC, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006;42:389-391
5. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993;25:97-108.
6. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999;48:707-710
7. McDougal LK, Steward CD, Killgore GE, et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: Establishing a national database. J Clin Microbiol 2003;41:5113-5120
8. Aiello AE, Lowy FD, Wright LN, et al. Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: Review and recommendations for future studies. Lancet Infect Dis 2006;6:335-341
9. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin- resistant Staphylococcus aureus among professional football players. N Engl J Med 2005;352:468-475
10. Mishaan AM, Mason EO Jr, Martinez-Aguilar G, et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr Infect Dis J 2005;24: 201-206
11. Kobayashi SD, DeLeo FR. An update on community-associated MRSA virulence. Curr Opin Pharmacol 2009;9:545-551
12. Tenover FC, McDougal LK, Goering RV, et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 2006;44:108-118
13. Kennedy AD, Otto M, Braughton KR, et al. Epidemic communityassociated methicillin-resistant Staphylococcus aureus: Recent clonal expansion and diversification. Proc Natl Acad Sci U S A 2008;105: 1327-1332
14. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42:647-656
15. Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23:99-139.
16. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006;42(suppl 1):S25-34.
17. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46(suppl 5):S360-7.
18. Rybak MJ, Cha R, Cheung CM, et al. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. Diagn Microbiol Infect Dis 2005;51:119-125
19. Jones RN. Microbiological features of vancomycin in the 21st century: Minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006;42(suppl 1):S13-24.
20. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-1705
21. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-2402
22. Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44:3883-3886
23. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 2006;166:2138-2144
24. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-3320
25. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46: 193-200. (Pubitemid 351269157)
26. Yoon YK, Kim JY, Park DW, et al. Predictors of persistent methicillin- resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 2010;65:1015-1018
27. Clinical Laboratory Standards Institute. Performance standards for antimicrobial disc susceptibility tests: 15th information supplement. Report no. M100-S15. Wayne (PA): Clinical Laboratory Standards Institute; 2005.
28. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-680
29. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Staphylococcus aureus accessory gene regulator (agr) group II: Is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003;187:929-938
30. Verdier I, Reverdy ME, Etienne J, et al. Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II. Antimicrob Agents Chemother 2004;48:1024-1027
31. Wootton M, Howe RA, Hillman R, et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001;47:399-403.
32. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44:1208-1215
33. Rybak MJ, Leonard SN, Rossi KL, et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008;46:2950-2954
34. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: Trends over 11 years. J Clin Microbiol 2009;47: 1640-1644
35. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003;36:429-439
36. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-528
37. Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-451
38. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004;39:539-545
39. Lodise TP, Miller CD, Graves J, et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;62:1138-1141
40. Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:85-90.
41. Sieradzki K, Tomasz A. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 2003;185:7103-7110
42. Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: A review of the global challenge. J Infect 2009;59(suppl 1):S4-16.
43. Howden BP, Smith DJ, Mansell A, et al. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol 2008;8:39.
44. Peleg AY, Monga D, Pillai S, et al. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis 2009;199:532-536
45. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-136
46. Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 7th ed. CLSI document M7-A8. Wayne (PA): Clinical Laboratory Standards Institute; 2009.
47. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin- resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-1347
48. Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: A consequence of medical progress. JAMA 2005;293: 3012-3021
49. Cosgrove SE, Fowler VG Jr. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46(suppl 5):S386-93.
50. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003;36:53-59
51. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44:190-196
52. Maor Y, Rahav G, Belausov N, et al. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007;45:1511-1514
53. Maor Y, Hagin M, Belausov N, et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009;199:619-624
54. Fong RK, Low J, Koh TH, et al. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 2009;28:983-987
55. Rong SL, Leonard SN. Heterogeneous vancomycin resistance in Staphylococcus aureus: A review of epidemiology, diagnosis, and clinical significance. Ann Pharmacother 2010;44:844-850
56. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46(suppl 5):S378-85.
57. Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005;41:583-590
58. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukoci-din and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359:753-759
59. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: Results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-3862
60. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilatorassociated pneumonia. Chest 1998;113:412-420
61. Kim SH, Park WB, Lee KD, et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003;37:794-799
62. Niederman MS. Treatment options for nosocomial pneumonia due to MRSA. J Infect 2009;59(suppl 1):S25-31.
63. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU- 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-412
64. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-1797
65. Wunderink RG, Cammarata SK, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-992
66. Beibei L, Yun C, Mengli C, et al. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: Meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2010;35:3-12.
67. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis 2005;191:2149-2152
68. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-674
69. King MD, Humphrey BJ, Wang YF, et al. Emergence of community- acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-317
70. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(suppl 5):S368-77.
71. Proctor RA. Role of folate antagonists in the treatment of methicillinresistant Staphylococcus aureus infection. Clin Infect Dis 2008;46: 584-593
72. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
73. Wang JL, Hsueh PR. Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother 2009; 10:785-796
74. Poh CH, Oh HM, Tan AL. Epidemiology and clinical outcome of enterococcal bacteraemia in an acute care hospital. J Infect 2006;52: 383-386
75. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Infect Control 2006;34:S11-9; discussion S64-73.
76. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology 2009;155:1749-1757
77. Arias CA, Contreras GA, Murray BE. Management of multi-drug resistant enterococcal infections. Clin Microbiol Infect 2010;6: 555-562
78. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-721
79. Werner G, Coque TM, Hammerum AM, et al.Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008;13:pii:19046.
80. Livermore DM. Future directions with daptomycin. J Antimicrob Chemother 2008;62(suppl 3):iii41-9.
81. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
82. Allington DR, Rivey MP. Quinupristin/dalfopristin: A therapeutic review. Clin Ther 2001;23:24-44.
83. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008;27:3-15.
84. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/ dalfopristin. Clin Infect Dis 2001;33:1816-1823
85. Vinh DC, Rubinstein E. Linezolid: A review of safety and tolerability. J Infect 2009;59(suppl 1):S59-74.
86. Meka VG, Pillai SK, Sakoulas G, et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004;190:311-317
87. Mendes RE, Deshpande LM, Castanheira M, et al. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008;52:2244-2246
88. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolidresistant Staphylococcus aureus. Clin Infect Dis 2010;50:821-825
89. Papadopoulos A, Plachouras D, Giannitsioti E, et al. Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: A case-control study. J Chemother 2009;21:165-169
90. Carpenter CF, Chambers HF. Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000.
91. Moise PA, North D, Steenbergen JN, et al. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: Facts and assumptions. Lancet Infect Dis 2009;9:617-624
92. Bliziotis IA, Plessa E, Peppas G, et al. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: A meta-analysis. Ann Pharmacother 2010;44:97-106.
93. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-665
94. Rice DA, Mendez-Vigo L. Daptomycin in bone and joint infections: A review of the literature. Arch Orthop Trauma Surg 2009;129:1495-1504
95. Peterson LR. A review of tigecycline-the first glycylcycline. Int J Antimicrob Agents 2008;32(suppl 4):S215-22.
96. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(suppl 5):S341-53.
97. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005;41(suppl 5):S354-67.
98. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumo-nia: Results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009;63:52-61.
99. Saravolatz LD, Stein GE, Johnson LB. Telavancin: A novel lipoglycopeptide. Clin Infect Dis 2009;49:1908-1914
100. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46:1683-1693
101. Barbour A, Schmidt S, Rand KH, et al. Ceftobiprole: A novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2009;34:1-7.
102. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44.
103. Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-655
104. Stryjewski ME, Corey GR. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care 2009;15:403-412
105. Llarrull LI, Fisher JF, Mobashery S. Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge. Antimicrob Agents Chemother 2009;53:4051-4063
106. Talbot GH, Thye D, Das A, et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51: 3612-3616
107. Sincak CA, Schmidt JM. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. Ann Pharmacother 2009;43:1107-1114
108. Koga T, Masuda N, Kakuta M, et al. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52:2849-2854
109. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: Oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010;30:80-94.